腹主动脉瘤合并结直肠癌的序贯微创治疗:单中心经验
本研究回顾性纳入24例腹主动脉瘤合并结直肠癌患者,均先行EVAR再行腹腔镜结直肠切除,评估序贯两阶段微创治疗的安全性和可行性。结果显示EVAR后主要并发症率8.3%,结直肠术后12.5%,住院期间无死亡,总体死亡率20.8%,中位随访39.41个月。结论认为该方案安全可行,值得临床采用。
要点
- 腹主动脉瘤合并结直肠癌患者可先行EVAR再行腹腔镜结直肠切除。
- EVAR后主要并发症率8.3%,结直肠术后12.5%,住院期间无死亡。
- 总体死亡率20.8%,中位随访39.41个月。
核心结论
- 择期序贯两阶段微创治疗腹主动脉瘤合并结直肠癌安全可行,并发症率和死亡率可接受,应纳入当前临床实践。
研究设计与样本
- 回顾性单中心研究,2008年1月至2020年12月连续纳入24例腹主动脉瘤合并结直肠癌患者,均接受EVAR后腹腔镜结直肠切除的序贯两阶段微创治疗。
主要发现
- 动脉瘤位于肾下腹主动脉23例,髂总动脉1例;EVAR均首先进行,18例经皮入路,6例外科入路。
- 结肠癌12例位于左半结肠,9例右半结肠,3例直肠癌;腹腔镜手术无中转开腹或术中并发症。
- EVAR后主要并发症率8.3%,结直肠术后12.5%;EVAR与结直肠治疗平均间隔7.8±1天,平均住院日15.4±3.6天。
- 住院期间及两次手术间无死亡;总体死亡率20.8%,平均随访39.41±19.2个月。
临床怎么用
- 对于合并腹主动脉瘤和结直肠癌的患者,可考虑先行EVAR再行腹腔镜结直肠切除的序贯微创方案。
局限性
- 回顾性单中心设计,样本量24例,随访时间平均39.41个月,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The surgical management of concomitant occurrence of abdominal aortic aneurysm (AAA) and colorectal cancer (CRC) is still controversial. Conversely, benefits from a minimally invasive approach are well known concerning the treatment of both AAA and CRC. The aim of this study is to assess safety and feasibility of a sequential 2-staged minimally invasive during the same recovery by endovascular aneurysm repair (EVAR) technique and laparoscopic colorectal resection. METHODS: From January 2008 to December 2020, all patients with concomitant AAA and CRC were consecutively treated by EVAR and laparoscopic colorectal resection. Perioperative data were retrospectively collected in order to evaluate short- and long-term outcomes following the sequential 2-staged procedures. RESULTS: A total of 24 patients were included. The localization of the aneurysm was infrarenal abdominal aortic in 23 cases and in one case of common iliac artery. EVAR procedure has always been performed first. In 18 patients, a percutaneous access has been used while in 6 patients a surgical access has been adopted. Twelve patients had cancer in the left colon, 9 in the right colon, and 3 patients had rectal cancer. No conversions or intraoperative complications had occurred during laparoscopic surgery. The major complications rate after EVAR and CRC surgery was 8.3% and 12.5%, respectively. The mean interval between EVAR and CRC treatment was 7.8 ± 1 and the mean length of stay was 15.4 ± 3.6. No deaths occurred during hospitalization and between the procedures. Overall mortality was 20.8% with a mean follow-up of 39.41 ± 19.2 months. CONCLUSION: Elective sequential 2-staged minimally invasive treatment is a safe and feasible approach with acceptable morbidity and mortality rates and it should be adopted in current clinical practice to manage concomitant AAA and CRC.
引用
- Bracale U, Di Nuzzo MM, Bracale UM, et al. Sequential Minimally Invasive Treatment of Concomitant Abdominal Aortic Aneurysm and Colorectal Cancer: A Single-Center Experience. Ann Vasc Surg. 2021. PMID: 34492315. doi:10.1016/j.avsg.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。